Macrogenics Inc (NASDAQ: MGNX) kicked off on Tuesday, up 9.35% from the previous trading day, before settling in for the closing price of $1.39. Over the past 52 weeks, MGNX has traded in a range of $0.99-$16.58.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 45.47%. While this was happening, its average annual earnings per share was recorded -140.19%. With a float of $58.00 million, this company’s outstanding shares have now reached $62.82 million.
Let’s determine the extent of company efficiency that accounts for 341 employees. In terms of profitability, gross margin is 89.25%, operating margin of -74.54%, and the pretax margin is -44.51%.
Macrogenics Inc (MGNX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Macrogenics Inc is 8.07%, while institutional ownership is 82.24%. The most recent insider transaction that took place on Feb 15 ’25, was worth 1,083. In this transaction VP, Controller & Treasurer of this company sold 423 shares at a rate of $2.56, taking the stock ownership to the 9,532 shares.
Macrogenics Inc (MGNX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -140.19% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -28.62% during the next five years compared to 19.47% growth over the previous five years of trading.
Macrogenics Inc (NASDAQ: MGNX) Trading Performance Indicators
Take a look at Macrogenics Inc’s (MGNX) current performance indicators. Last quarter, stock had a quick ratio of 3.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.07, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -1.75 in one year’s time.
Technical Analysis of Macrogenics Inc (MGNX)
Looking closely at Macrogenics Inc (NASDAQ: MGNX), its last 5-days average volume was 0.7 million, which is a drop from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 84.57%. Additionally, its Average True Range was 0.17.
During the past 100 days, Macrogenics Inc’s (MGNX) raw stochastic average was set at 19.06%, which indicates a significant decrease from 94.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 100.35% in the past 14 days, which was higher than the 75.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9534, while its 200-day Moving Average is $3.2125. However, in the short run, Macrogenics Inc’s stock first resistance to watch stands at $1.6000. Second resistance stands at $1.6800. The third major resistance level sits at $1.8100. If the price goes on to break the first support level at $1.3900, it is likely to go to the next support level at $1.2600. Now, if the price goes above the second support level, the third support stands at $1.1800.
Macrogenics Inc (NASDAQ: MGNX) Key Stats
The company with the Market Capitalisation of 95.90 million has total of 63,090K Shares Outstanding. Its annual sales at the moment are 149,960 K in contrast with the sum of -66,970 K annual income. Company’s last quarter sales were recorded 19,350 K and last quarter income was -15,420 K.
